Alkermes generated Q4 2025 total revenues of 384547000, driven by total proprietary net sales of 315492000, and reported GAAP net income of 49341000 with diluted EPS of 0.29, supported by growth in LYBALVI.

Alkermes plc delivered a successful third quarter in 2025, marked by strong revenue growth and robust profitability, driven by solid performance across its commercial portfolio. The company reported total revenues of $394.2 million and GAAP net income of $82.8 million, with diluted GAAP earnings per share of $0.49. Alkermes also ended the quarter in a strong financial position with $1.14 billion in cash, cash equivalents, and total investments, and subsequently raised its financial outlook for the full year 2025.

Alkermes reported total revenue of $390.7 million and GAAP net income of $87.1 million in Q2 2025, driven by double-digit growth in LYBALVI, ARISTADA, and VIVITROL. The company maintained robust operating margins and reiterated its 2025 financial guidance.

Alkermes plc reported first quarter 2025 revenues of $306.5 million and GAAP net income of $22.5 million, with diluted GAAP earnings per share of $0.13. The company reiterated its 2025 financial expectations and highlighted progress in its ALKS 2680 development program.

Alkermes reported total Q4 2024 revenue of $430.0 million, up from $377.5 million in Q4 2023. Net income from continuing operations reached $145.7 million, while non-GAAP net income stood at $173.4 million. Adjusted EBITDA from continuing operations was $170.0 million. Revenue growth was driven by proprietary products, including VIVITROL, ARISTADA, and LYBALVI.

Alkermes reported third-quarter revenues of $378.1 million, with net sales of proprietary products increasing approximately 18% year-over-year. GAAP net income from continuing operations was $92.8 million, with diluted GAAP earnings per share from continuing operations of $0.56. The company reiterated its 2024 financial expectations.

Alkermes reported second quarter revenues of $399.1 million. GAAP net income from continuing operations was $94.7 million, with diluted GAAP earnings per share from continuing operations of $0.55. The company reiterated its 2024 financial expectations.

Alkermes reported a solid first quarter in 2024 with total revenues of $350.4 million and GAAP net income from continuing operations of $38.9 million. The company is advancing its strategic priorities, including LYBALVI's prescription growth and ALKS 2680's development.

Alkermes reported Q4 2023 financial results, with total revenues of $377.5 million. The company's proprietary product net sales increased year-over-year. GAAP net income for the quarter was $112.8 million. The company provided financial expectations for 2024, including generating a 30% EBITDA margin.

Alkermes reported Q3 2023 financial results with total revenues of $380.9 million and GAAP net income of $47.8 million. Net sales of proprietary products increased approximately 16% year-over-year. The company reiterated its financial expectations for full-year 2023 and expects to complete the separation of its oncology business in November 2023.

Alkermes reported strong Q2 2023 financial results, with total revenues of $617.4 million, including $248.4 million from the Janssen arbitration. Net sales of proprietary products increased by 21% year-over-year. The company reiterated its financial expectations for the full year 2023.

Alkermes plc reported first-quarter 2023 financial results, with total revenues of $287.6 million. The company saw strong performance in its proprietary product portfolio, with a 25% increase in net sales year-over-year. Alkermes is reiterating its financial expectations for 2023 and is progressing with the planned separation of its oncology business.

Alkermes plc reported Q4 2022 financial results, with total revenues of $304.7 million compared to $324.5 million for the same period in the prior year. GAAP net loss was $28.3 million, or a loss of $0.17 per share, while non-GAAP net income was $24.2 million, or $0.14 per share.

Alkermes reported Q3 2022 financial results, with total revenues of $252.4 million. Net sales of proprietary products were $199.4 million, reflecting growth in VIVITROL, ARISTADA, and LYBALVI. The company announced its intent to separate its neuroscience and oncology businesses and updated its financial expectations for full-year 2022.

Alkermes reported Q2 2022 financial results with total revenues of $276.2 million. Net sales of proprietary products were $190.8 million, driven by VIVITROL, ARISTADA, and LYBALVI. The company raised its financial expectations for full-year 2022.

Alkermes plc reported first quarter 2022 financial results, with total revenues of $278.5 million compared to $251.4 million for the same period in the prior year. The company reported a GAAP loss per share of $0.22 and non-GAAP earnings per share of $0.12. They reiterated their financial expectations for 2022.

Alkermes reported Q4 2021 revenues of $324.5 million and GAAP net income of $0.9 million, or $0.01 per share. Non-GAAP net income was $38.5 million, or $0.23 per share. The company provided financial expectations for 2022, reflecting a focus on proprietary products and continued operating efficiency.

Alkermes plc reported third-quarter 2021 financial results, with total revenues of $294.1 million, an 11% increase year-over-year. The company reported a GAAP net loss of $29.0 million, or $0.18 per share, and non-GAAP net income of $23.6 million, or $0.14 per share. They reiterated their financial expectations for 2021.

Alkermes plc reported a strong second quarter in 2021, with total revenues of $303.7 million, a 23% increase year-over-year. The company's performance was driven by commercial execution, with VIVITROL® and ARISTADA® demonstrating robust growth. Alkermes updated its full-year 2021 financial expectations based on this strong first-half performance.

Alkermes reported first quarter revenues of $251.4 million, reflecting solid performance of VIVITROL and ARISTADA. The company achieved a GAAP loss per share of $0.14 and non-GAAP earnings per share of $0.11. They reiterated their financial expectations for 2021.

Alkermes reported Q4 2020 revenues of $280.0 million and a GAAP net loss of $42.6 million, or a loss per share of $0.27. Non-GAAP net income was $16.5 million, or earnings per share of $0.10.

Alkermes plc reported Q3 2020 financial results with total revenues of $265.0 million. The company reported a GAAP net loss per share of $0.00 and non-GAAP earnings per share of $0.26. Strong commercial execution and disciplined expense management led to raised financial expectations for 2020.

Alkermes plc reported second quarter revenues of $247.5 million, GAAP net loss per share of $0.19 and diluted non-GAAP earnings per share of $0.06. The company is focused on commercial execution, aggressive development of pipeline programs, and efficient management of operating structure.

Alkermes reported Q1 2020 revenues of $246.2 million, primarily driven by a 30% year-over-year growth of proprietary product net sales. The company reported a diluted GAAP net loss per share of $0.24 and diluted non-GAAP earnings per share of $0.01. Due to COVID-19 uncertainties, the company withdrew its previously provided 2020 financial expectations.

Alkermes plc reported Q4 2019 financial results, with total revenues of $412.7 million compared to $315.8 million for the same period in the prior year. The company reported a GAAP net loss of $5.4 million, or $0.03 per share, and non-GAAP net income of $131.4 million, or $0.83 per share.